Cargando...
Sacituzumab govitecan: Antibody-drug conjugate in triple negative breast cancer and other solid tumors
Patients with metastatic triple negative breast cancer (mTNBC) that has progressed on first-line therapy have a poor prognosis with limited therapeutic options. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate (ADC) that has shown promising efficacy in mTNBC. SG is comprised of SN-38, t...
Gardado en:
| Publicado en: | Drugs Today (Barc) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7303962/ https://ncbi.nlm.nih.gov/pubmed/31584574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1358/dot.2019.55.9.3039669 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|